Thomas Barwick Topline Summary and Update Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a long-struggling commercial-stage biotech working on developing the market for their nuclear exportin 1 inhibitor selinexor. While it is currently approved to treat multiple myeloma in later lines of therapy, KPTI is on track to potentially expand the label into endometrial cancer, with a phase 3 trial eagerly anticipated (though still a ways away). Now that we know the abstracts being presented at the American Society ...